Abstract
Background Pregnancy in women with multiple sclerosis (MS) is associated with a reduction of long-term disability progression. The mechanism that drives this effect is unknown, but converging evidence suggests a role for epigenetic mechanisms altering immune and/or central nervous system function.
Objectives We aimed to identify whole blood and immune cell-specific DNA methylation patterns associated with parity in relapse-onset multiple sclerosis.
Methods We compared whole-blood methylation patterns between 96 matched pairs of nulligravida and parous females with MS (n=192). Parity was defined as at least one term or pre-term birth, and nulligravida was defined as no prior pregnancies. Methylation was measured with Illumina EPIC arrays, and data was pre-processed and statistically analysed using the ChAMP package. Cell-type proportions were estimated using the EpiDISH package, and cell-specific analysis conducted using linear regression. Gene-set enrichment analysis (GSEA) was performed with ToppGene API and GOmeth. Methylation age was calculated with the methyAge package. Methylation age acceleration (MAA) was calculated by regressing methylation age on chronological age. FDR<0.05 was used to assess significance.
Results The median time from last pregnancy to blood collection was 16.66 years (range = 1.45 – 44.42 years). We identified 903 differentially methylated positions (DMPs) in whole blood; 365 were hypomethylated and 528 were hypermethylated in parous women. We further identified two differentially methylated regions (DMRs) in CRYGN on Chromosome 7 and an intergenic region on Chromosome 15. There were four and eight cell type specific DMPs in CD4+ and CD8+ cells, respectively. Differentially methylated genes were enriched in neuronal plasticity pathways. Parity was associated with reduced MAA by a mean of 1.44 to 2.27 years using the PhenoAge (p = 0.002) and GrimAge (p = 0.005) algorithms.
Conclusion Whole-blood methylation patterns are associated with birth history in females with relapse-onset multiple sclerosis. We found enrichment of differentially methylated genes encoding neuronal processes and reduced MAA in parous women. These methylation changes could mediate the long-term benefit of pregnancy for disease progression in multiple sclerosis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was financially supported by an MSRA Project Grant (18-0424), RMH Home Lottery Grant (MH2013-055), MSBase Foundation Project Grant, Charity Works for MS Project Grant, Pennycook Foundation Grant 2018, and a Monash University Project Grant.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval for the collection of demographic, clinical, treatment and pregnancy history data via the MSBase Registry9 was obtained from the Alfred Health Human Research Ethics Committee (528/12), and institutional review boards at all participating centres. Approval for the collection of genetic data was obtained from the Australian National Mutual Acceptance Scheme (HREC/13/MH/189). Written informed consent was obtained from participants as per local laws at each study site.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Access requests for methylation data with scientifically sound proposals can be made in writing to Dr. Vilija Jokubaitis (vilija.jokubaitis{at}monash.edu) and Prof. Jeannette Lechner-Scott (Jeannette.LechnerScott{at}health.nsw.gov.au). Requests will be assessed and responded to within 4 weeks. If data access is approved, authorship should include the MSBase Genetics Consortium, with individual authors listed as appropriate.
